Genelabs Technologies will collaborate with Taiwan’s National Health Research Institutes (NHRI), a governmental non-profit foundation, and Genovate Biotechnology of Taiwan to research and develop compounds that target the hepatitis C virus (HCV). According to Genelabs, the collaboration will combine Genelabs lead compounds on an existing target with NHRI’s chemistry and drug discovery abilities. More details...

Stock Symbol: (NSDQ: GNLB)